Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

被引：0
|
作者：
Ramalingam, S. [1 ]
Arora, S. [2 ]
Neibauer, M. Whipple [2 ]
Zhou, J. [2 ]
Hazard, S. [3 ]
Frenkl, T. [2 ]
Stojadinovic, A. [2 ]
Peters, S. [4 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Glaxosmithkline, Philadelphia, PA USA
[3] Glaxosmithkline, Waltham, MA USA
[4] Lausanne Univ, Oncol, Lausanne, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
NSCLC; PARP inhibitor; niraparib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P83.02
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
    Yang, J. C-H.
    Luft, A.
    De la Mora Jimenez, E.
    Lee, J. S.
    Koralewski, P.
    Karadurmus, N.
    Sugawara, S.
    Livi, L.
    Basappa, N. S.
    Quantin, X.
    Dudnik, J.
    Moran Ortiz, D.
    Mekhail, T.
    Okpara, C. E.
    Zimmer, Z.
    Samkari, A.
    Bhagwati, N.
    Csoszi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1429 - S1430
  • [42] TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
    Okamoto, I.
    Kuyama, S.
    Girard, N.
    Lu, S.
    Franke, F. A.
    Pan, E.
    Ren, N.
    Chen, A.
    Oputa, E.
    Lisberg, A. E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [43] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Waldschmidt, D.
    El-Khoueir, A. B.
    Kim, R. D.
    Harris, W. P.
    Sung, M. W.
    Iqbal, S.
    Zhang, A.
    Nakajima, K.
    Galle, P. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 123 - 123
  • [45] Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti PD-1/PD-L1 agents: Phase 2 LEAP 004 study.
    Fernandez, Ana Maria Arance
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Daud, Adil
    Eggermont, Alexander M.
    Hauschild, Axel
    Kluger, Harriet M.
    Taylor, Matthew H.
    Smith, Alan
    Chen, Ke
    Krepler, Clemens
    Diede, Scott J.
    O'Day, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
    Dzienis, M. R.
    Cundom, J. E.
    Fuentes, C. S.
    Hansen, A. R.
    Nordlinger, M. J.
    Pastor, A. V.
    Oppelt, P.
    Neki, A.
    Gregg, R. W.
    Lima, I. P. F.
    Franke, F. A.
    Da Cunha Junior, G. F.
    Tseng, J. E.
    Loree, T.
    Joshi, A. J.
    Mccarthy, J. S.
    Naicker, N.
    Sidi, Y.
    Gumuscu, B.
    De Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S839 - S840
  • [47] A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC
    Mok, T. S. K.
    Jotte, R. M.
    Cappuzzo, F.
    Reck, M.
    Papadimitrakopoulou, V.
    West, H. J.
    Sandler, A.
    Mocci, S.
    Coleman, S.
    Asakawa, T.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
    Weickhardt, Andrew James
    Van der Heijden, Michiel Simon
    Balar, Arjun Vasant
    Shariat, Shahrokh F.
    Shore, Neal D.
    Fang Xiao
    Godwin, James Luke
    Kapadia, Ekta
    Michalski, Jeff M.
    James, Nicholas D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [49] QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC
    Yang, Yun-Peng
    Ma, Yu-Xiang
    Huang, Yan
    Zhao, Yuan-Yuan
    Fang, Wen-Feng
    Hong, Shao-Dong
    Tian, Ying
    Xue, Cong
    Sheng, Jin
    Zhang, Li
    SCIENTIFIC REPORTS, 2015, 5
  • [50] QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC
    Yun-Peng Yang
    Yu-Xiang Ma
    Yan Huang
    Yuan-Yuan Zhao
    Wen-Feng Fang
    Shao-Dong Hong
    Ying Tian
    Cong Xue
    Jin Sheng
    Li Zhang
    Scientific Reports, 5
12345